Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

This article sheds light on the various scaffolds that can be used in the designing and
development of novel synthetic compounds to create DPP-4 inhibitors for the treatment of …

Diabetes mellitus (DM) is a real challenge to the recent era and is one of the major diseases
for initiating life-threatening disorders. In current research, a compound was designed by …

One of the largest classes of organic molecules are dihydropyrimidines and its derivatives.
They are widely used in a variety of pharmacological and industrial applications. Their …

Current oral medications for type 2 diabetes target a single main physiological mechanism.
They either activate or inhibit receptors to enhance insulin sensitivity, increase insulin …

Diabetes mellitus (DM) is a frequent medical problem, affecting more than 4% of the
population in most countries. In the context of diabetes, the vascular endothelium can play a …

Bioactive peptides are released during the production of fermented dairy, vegetables, fruits,
legumes, fish, and meat products. The proteolytic specificity of lactic acid bacteria, Bacillus …

Aim: To develop imeglimin-inspired novel 1, 3, 5-triazine derivatives as antidiabetic agents.
Materials & methods: These derivatives were synthesized and tested against DPP enzymes …

A novel series of 4-aminopiperidin-3, 4-dihyroquinazoline-2-uracil derivatives (9a-9 L) were
logically designed and synthesized as potent DPP4 inhibitors as antidiabetic agents …

Beta‐blockers are commonly used medications that antagonize β‐adrenoceptors, reducing
sympathetic nervous system activity. Emerging evidence suggests that beta‐blockers may …